Ipca Labs plant blasted by FDA for a 'cascade of failure'

FDA Building 2
The FDA has issued a 10-page Form 483 for an Ipca Laboratories plant in India that has previously be criticized for manufacturing failures. (FDA)

An Ipca Laboratories plant savaged in an FDA warning letter three years ago continues to fail manufacturing standards that would assure its drugs are safe and effective. The FDA says that is “demonstrated by a cascade of failure” in the quality unit of the Indian plant. 

These failures at the finished products plant in Silvassa are detailed (PDF) in an FDA Form 483 that followed an inspection last month. There are only three observations, but the list of issues stretches to 10 pages. 

RELATED: FDA warning to Ipca Labs shines light on rampant data falsification


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

It says the plant quality unit allows batches to be released for use without properly reviewing out-of-specification and out-of-trend investigations, routine quality control (QC) testing worksheets or electronic data to ensure they meet standards.  

It says some corrective actions on change of controls were open for two years while analysts have not properly followed dissolution testing procedures for more than a decade. 

RELATED: India's troubled Ipca buys U.S. API maker 

The FDA has been down this road with Ipca before. The Silvassa plant was one of three that was slammed in a warning letter in 2016 for serious data manipulation and falsification. The FDA said the problem was rampant at that company, enforced by senior managers in the QC unit to keep product supply flowing.

Ipca has told the FDA in the past that it will get the problems under control, and the problems have not kept it from expanding in the U.S. Last year, it paid nearly $10 million for Pisgah Labs, an API maker based in Pisgah Forest, North Carolina.

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.